Comparative oncology clinical trials play an important and growing role in cancer research
and drug development efforts. These trials, typically conducted in companion (pet) dogs …

Pet dogs develop spontaneous cancers at a rate estimated to be five times higher than that
of humans, providing a unique opportunity to study disease biology and evaluate novel …

Background In humans, muscle-invasive bladder cancer (MIBC) is highly aggressive and
associated with a poor prognosis. With a high mutation load and large number of altered …

Epidermal growth factor receptors 1 and 2 (EGFR and HER2) are frequently overexpressed
in various malignancies. Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR …

Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC)
harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found …

Background Early detection and intervention research is expected to improve the outcomes
for patients with high grade muscle invasive urothelial carcinoma (InvUC). With limited …

Dog bladder cancer (BC) is mostly muscle-invasive (MI) with poor prognosis, and its
pathogenesis is close to human MIBC. Three-dimensional (3D) organoid culture ensures …

Simple Summary In canine urothelial carcinoma, the BRAF gene is frequently mutated
(V595E). To detect this mutation, urine or tissue samples are currently tested by PCR …

BRAF-targeted therapies including vemurafenib (Zelboraf) induce dramatic cancer
remission; however, drug resistance commonly emerges. The purpose was to characterize a …

Simple Summary Laboratory experiments studying solid tumors are limited by the inability to
adequately model the tumor microenvironment and important immune interactions. Immune …